Forma Therapeutics Holdings Inc. shares traded 51% higher yesterday after the company reported it agreed to be acquired by Denmark s Novo Nordisk A/S in an all-cash deal for $20.00 per share. With the acquisition, Novo Nordisk aims to expand its global presence in the treatment of rare blood disorders and sickle cell disease.